The risk of atherosclerotic cardiovascular disease (ASCVD) increases in patients, who already have mutations in FH genes such as LDLR, PCSK9 or ApoB, when compared to patients without any mutation, but with similar cholesterol levels [2]. This evidence concerns the gene APOB and atherosclerosis.